LNTH
Lantheus Holdings, Inc.Price & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Free cash flow | $121.9M | the three months ended March 31, 2026 | — |
| Sales of DEFINITY | $84.6M | the three months ended March 31, 2026 | — |
| Sales of Neuraceq | $35.4M | the three months ended March 31, 2026 | — |
| Sales of PYLARIFY | $240.9M | the three months ended March 31, 2026 | — |
| DFINITY year-over-year revenue growth | 6.8% | Q1 FY2026 call | — |
| NeuroSeq PMF footprint | 22 | Q1 FY2026 call | — |
| NeuroSeq revenue growth | 14.3% | Q1 FY2026 call | — |
| U.S. volume growth | 5.8% | Q1 FY2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LNTH
this stock
Lantheus Holdings, Inc.
|
$6.85B | +56.8% | +3.6% | 25.1 | 9.7% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$52.45B | +5.5% | — | — | 0.2% |
|
GALDY
Galderma Group AG/ADR
|
$48.68B | -0.2% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$42.98B | -3.6% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LNTH | -2.3% | -0.3% | +57.0% | -6.0% | +56.8% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | -3.5% | -0.2% | +46.9% | -7.1% | +46.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.